Product Name: PKN1 (771-777) pT774
Product Number: PE-04ADX99
Size: | 200 µg | | Price: | 42.00 |
| 1 mg | | $US | 84.00 |
| 5 mg | | | 185.00 |
Peptide Name: PKN1 (771-777) pT774
Product Use: Services as a blocking peptide for use with the PRK1-pT774 rabbit polyclonal antibody (Cat. No.: AB-PK781) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T774 phosphorylation stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RTS-pT-FCG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Scientific Background: PRK1 (PKN1) is a protein-serine/threonine kinase of the AGC group and PKN family. It is associated with many functions including regulation of actin cytoskeleton, cell migration, and tumour cell invastion. Its phosphotransferase activity is stimulated upon binding to Rho proteins (RHOA, RHOB and RAC1). It is activated by lipids, particularly cardiolipin and to a lesser extent by other acidic phospholipids. It is also activated by caspase-3 (CASP3) cleavage during apoptosis., as well as in vitro by limited proteolysis by trypsin. Phosphorylationof PRK1 at T774 (activation loop of the kinase domain) and S916 (turn motif) increases phosphotransferase activity. Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis. Stimulation of the PRK1 signalling cascade results in androgen receptor superactivation in human prostate cancer cells. PRK1 also represses Wnt signalling in human melanoma cells.